Responsibility in Drug Advertising Act of 2024
Latest Action
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Official Summary
Official summary has not been imported yet.
GovScope Watchdog™
AI Government Intelligence™The Responsibility in Drug Advertising Act of 2024 is a Senate bill introduced in the 118th Congress aimed at regulating drug advertising practices. The bill was read twice and referred to the Senate Committee on Health, Education, Labor, and Pensions but did not advance further and is currently classified as failed or expired. No official summary or full text is publicly available, limiting detailed analysis of its provisions. The bill falls under the health policy area and appears to focus on ensuring accountability in pharmaceutical advertising, although specific measures are not documented in the available data.
This bill sought to address drug advertising responsibilities but did not progress beyond committee referral and has expired without enactment.
- Introduced in the Senate during the 118th Congress as S.4785.
- Referred to the Senate Committee on Health, Education, Labor, and Pensions after being read twice.
- No official summary or full text is available, and the bill status is failed/expired.
['Consumers of pharmaceutical products who may receive clearer or more responsible drug advertising.', 'Regulatory agencies overseeing drug advertising standards.', 'Healthcare providers who rely on accurate drug information.']
['Lack of publicly available full text and summary limits understanding of implementation requirements and enforcement mechanisms.', 'Potential costs and administrative burdens on pharmaceutical companies and regulatory bodies are unknown.', 'Unclear authority and oversight provisions due to missing detailed legislative language.']
The bill was introduced in the Senate and referred to the relevant health committee but did not advance to further legislative stages. Its failure to progress suggests limited legislative momentum or prioritization during the 118th Congress. The absence of detailed public documentation restricts insight into the bill's specific policy proposals or legislative debates.
Hidden impact flags detected: 2
GovScope reviewed 2 policy-risk categories. Hover for a quick definition. Click detected flags for bill-specific details.
['If enacted, the bill could have influenced pharmaceutical marketing practices, potentially affecting consumer information and healthcare decision-making.', 'Changes in advertising regulations might have led to shifts in pharmaceutical industry marketing strategies and compliance costs.', 'Regulatory agencies might have required additional resources to enforce new advertising standards.']
The absence of an official summary and full bill text significantly limits the ability to conduct a thorough transparency and oversight analysis. This lack of documentation hinders public and stakeholder engagement and complicates assessment of the bill's potential impacts and enforcement mechanisms.
GovScope Intelligence Roadmap
Future bill intelligence will connect sponsors, committee referrals, related votes, campaign finance, disclosures, and stock trades into one legislative intelligence view.